Kezar Life Sciences, Inc. (2KZ.F)
| Previous Close | 0.7600 |
| Open | 0.7150 |
| Bid | 0.7600 x 0 |
| Ask | 0.7850 x 0 |
| Day's Range | 0.7150 - 0.7150 |
| 52 Week Range | 0.6150 - 2.8000 |
| Volume | |
| Avg. Volume | 1,969 |
| Market Cap | 52.839M |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 08, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 12,000 shares of its common stock with an exercise price of $0.93 per share, which is equal to the closing price of Kezar’s common stock on April 1, 2
- Business Wire
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., March 14, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.
- Business Wire
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., February 28, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate on the Cardiorenal Corporate Panel at the TD Cowen 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024, at 10:30 a.m. ET.
